# Pizarra — PT-pseudo_099651db404e (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_099651db404e
Task: 1

Encounter: Urology - outpatient on 17 Jan 2025.
Referrer: Dr. T. Hendriks (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 54-year-old male
  - PSA: 5.9 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.14 ng/mL²
  - PSA velocity: 0.97 ng/mL/yr
  - Prior PSA: 5.2 ng/mL
  - Prostate volume: 44.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7418201 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 5.9 ng/mL. PI-RADS 5. PSAD 0.14. Prostate volume 44 mL. csPCa 0.74.

Vitals: weight 113 kg, height 186 cm, BMI 32.7, BP 117/68 mmHg, HR 68 bpm. Smoking: Ex-smoker (39 pack-yr, quit 2010).

Chief complaint: Persistent elevation of prostate-specific antigen alongside a previous negative biopsy necessitates specialist review.

History: Originally referred for a 3.9 ng/mL prostate-specific antigen reading in 2022, this 54-year-old retired farmer has completed a negative biopsy yet continues to report moderate lower urinary tract symptoms, currently registering 13 on the IPSS questionnaire. He resides alone and has never married, maintaining his daily routine through a brisk 20-minute walk, accompanied by a modest three units of alcohol per week. His medical background remains clear apart from a substantial 39 pack-year smoking history, which he ceased in 2010. A recent audiology visit for routine hearing screening and his annual influenza vaccination proceeded without incident. Traveling over an hour by train for clinic appointments, he approaches his ongoing urological follow-up with a practical, straightforward mindset.

Physical examination: DRE: The prostate presents as symmetrically smooth, maintaining normal dimensions and consistency without palpable nodules or asymmetry. General examination shows stable vital signs and a BMI of 32.7, with no abdominal masses or lymphadenopathy detected. The individual appears well-nourished and ambulates without assistance.

Patient info: retired farmer; Never married; Lives alone.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 3 units / week; exercise Walking 20 min/day; IPSS score: 13/35 (moderate LUTS).

Recent other appointments: Audiology — hearing test; GP practice nurse — flu vaccination.
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.81 +/- 0.14   (95% CI 0.46-0.99)

Where the uncertainty comes from:
  - aleatoric  dA = 0.12  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.08  (few labelled cases resemble this one)
  - 7.3 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'firm': A +/- 1.96*dA does not cross the 0.5 threshold. On the 91 labelled cases this tier was never wrong, but it only covered 17 of them, so the 95% CI on that accuracy still reaches down to ~0.75. Treat it as a strong prior that should only be overturned by explicit contradicting evidence.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=1.0, psa=5.9, age=54.0, psad=0.14, dre_ord=0.0, vol=44.0, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the patient's PSA velocity (0.97 ng/mL/yr) and the specific PI-RADS 5 score in conjunction with the prior negative biopsy status. It also missed the context provided by the PSA history trend (which is not explicitly detailed beyond the current and prior PSA values) and the specific findings from the mpMRI report, which is crucial for interpreting the PI-RADS 5.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests a high probability (0.81) based on limited data. A failure mode is the high csPCa predicted probability (0.7418201) conflicting with the normal DRE and the prior negative biopsy. Another failure mode is the wide uncertainty interval ($\pm 0.14$), suggesting the model is highly uncertain, which could mean the true probability is near 0.5, making the strong prior unreliable. The prior does not account for the clinical significance of the PI-RADS 5 in the context of a prior negative biopsy.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report confirms high-grade features or specific lesion characteristics, it would increase the need for biopsy.
  <document> PSA history (trend) -> If the PSA velocity is significantly higher or the trend is more concerning than implied by the current values, it would increase the need for biopsy.
  <document> previous GP / urology consultation notes -> These notes might contain context regarding the LUTS or any prior discussions about the biopsy decision.
  <document> laboratory results (full panel) -> This could reveal other markers that modify the risk assessment.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line.

  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_099651db404e", "radiology_report": "OLVG Amsterdam Radiology | 15 Jan 2025 | Study: mpMRI prostate\n\nClinical Indication:\nA 54-year-old gentleman presents with a climbing PSA curve (current 5.9 ng/mL) and a previous negative TRUS biopsy, prompting re-evaluation for occult malignancy.\n\nFINDINGS:\nThe prostate gland measures 44.0 mL and exhibits asymmetry. A discrete abnormality occupies the right peripheral zone at the mid-gland level, spanning roughly 12 x 9 mm. T2-weighted sequences show pronounced hypointensity within this focus. Diffusion-weighted imaging confirms restricted water movement with correspondingly low ADC values. Dynamic contrast-enhanced phases demonstrate early, focal enhancement compared to adjacent tissue. There is no extraprostatic extension, seminal vesicle invasion, or suspicious pelvic lymphadenopathy.\n\nIMPRESSION:\nPI-RADS 5 lesion in the right mid peripheral zone. Prostate volume 44.0 mL yielding a PSA density of 0.14 ng/mL/mL. csPCa predicted probability 0.7418201."}

  **psa_trend**
  {"case_id": "PT-pseudo_099651db404e", "psa_trend": [{"date": "May 2022", "val": 3.4}, {"date": "Sep 2023", "val": 4.5}, {"date": "Jan 2025", "val": 5.9}]}

  **previous_notes**
  {"case_id": "PT-pseudo_099651db404e", "previous_notes": [{"date": "22 May 2024", "author": "Dr. T. Hendriks (GP)", "text": "Initial workup followed a PSA elevation to 3.9 ng/mL during May 2022. A subsequent climb to 5.2 ng/mL led to a systematic TRUS biopsy in late 2023, which returned entirely negative for malignancy. With PSA values remaining elevated and mild urinary complaints persisting, a urological re-evaluation was scheduled for further imaging and potential repeat sampling."}]}

  **laboratory_results**
  {"case_id": "PT-pseudo_099651db404e", "laboratory_results": [{"name": "PSA", "val": "5.9 ng/mL", "date": "23 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "1.39 ng/mL", "date": "23 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "24%", "date": "23 Dec 2024", "flag": ""}, {"name": "Haemoglobin", "val": "13.9 g/dL", "date": "23 Dec 2024", "flag": ""}, {"name": "WBC", "val": "6.6 x10^9/L", "date": "23 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "220 x10^9/L", "date": "23 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "75 umol/L", "date": "23 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "23 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "13.9 nmol/L", "date": "23 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "96 U/L", "date": "23 Dec 2024", "flag": ""}, {"name": "LDH", "val": "147 U/L", "date": "23 Dec 2024", "flag": ""}]}

NOT RETRIEVED
  get_family_history - Not called as per retrieval economy rules.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  PI-RADS 5 lesion in the right mid peripheral zone
  PSA velocity of 0.97 ng/mL/yr (based on trend data)
  csPCa predicted probability of 0.7418201

  AGAINST sampling this patient now:
  Normal DRE findings: Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done
  Prior biopsy: Negative

WHERE THIS LEANS
  The retrieved evidence strongly argues for sampling due to the high-risk PI-RADS 5 finding and the rising PSA velocity, which directly contradicts the negative prior biopsy. This leans toward a strong recommendation for biopsy.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the evidence strongly supports sampling due to the high-risk PI-RADS 5 lesion in the right mid peripheral zone and the rising PSA velocity of 0.97 ng/mL/yr, which directly contradicts the prior negative biopsy. The PI-RADS 5 finding and the PSA trend are the decisive factors driving this recommendation, overriding the negative prior result.

Variables that carried weight: bx=decisive, psa=decisive, vol=noted, psad=important, pirads=decisive
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
